Haloperidol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Haloperidol
- Haloperidol: From Schizophrenia to Congenital Disorder of Glycosylation with Defective Fucosylation
Haloperidol: From Schizophrenia to Congenital Disorder of Glycosylation with Defective Fucosylation
One-Sentence Summary
Haloperidol is a long-established antipsychotic, originally used for psychotic disorders, schizophrenia and Tourette syndrome. The TxGNN model predicts it may be effective for congenital disorder of glycosylation with defective fucosylation, but currently there are 0 clinical trials and 0 publications supporting this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Psychotic disorder, schizophrenia, schizophreniform and schizoaffective disorder, Tourette syndrome (taken from the knowledge graph, because the Singapore licence records contain no indication text) |
| Predicted New Indication | Congenital disorder of glycosylation with defective fucosylation |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Haloperidol is generally known as a dopamine D2 receptor antagonist, and its efficacy in psychosis and schizophrenia is well established.
The compiled data shows no mechanistic link between D2 antagonism and fucosylation or glycosylation pathways. The very high TxGNN score reflects a pattern in the knowledge graph, not biological or clinical evidence. This prediction should be treated as a hypothesis only, and it is not recommended for further investment without supporting data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN11076P | MANACE INJECTION 5 mg/ml | Injection | Duopharma (M) Sdn Bhd |
| SIN12245P | MYUNG IN HALOPERIDOL TABLET 1.5 mg | Tablet | Myung In Pharm Co Ltd |
| SIN11225P | MYUNG IN HALOPERIDOL INJECTION 5 mg/ml | Injection | Myung In Pharm Co Ltd |
| SIN09918P | HALOXEN 5 TABLET 5 mg | Tablet | Remedica Ltd |
All four registrations are valid single-ingredient products, available as oral tablets and injections.
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text):
- Cardiac rhythm: long QT syndrome (including familial), torsades de pointes
- Neurological: epilepsy, basal ganglia disease, focal hand dystonia, blepharospasm, neuroleptic malignant syndrome
- Haematological: neutropenia (including congenital forms), agranulocytosis, leukopenia
- Endocrine and metabolic: hypothyroidism, myxedema, potassium deficiency
- Other: liver disease, gallbladder disease, hypotensive disorder, female breast carcinoma
- Drug Interactions: 100 interactions are recorded. The listed examples include Major interactions with bupropion, morphine, clarithromycin and dolasetron, and many Moderate interactions, such as famotidine, epinephrine, hydrocortisone, amphotericin B, atropine and loperamide.
- Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction rests only on a graph-based score. There are no trials, no publications and no plausible mechanistic link to glycosylation biology. Haloperidol also carries a substantial safety and interaction burden.
To proceed, the following is needed:
- A mechanistic hypothesis linking haloperidol pharmacology to fucosylation pathways, with preclinical support
- Detailed mechanism of action data for haloperidol
- Official Singapore package insert warnings and contraindications
- An assessment of route and dosing feasibility for this rare genetic disorder
Note on other predictions: Among the other predicted indications, manic bipolar affective disorder has the strongest support (L1). It has a Phase 3 placebo- and haloperidol-controlled trial (NCT00129220, n=224) and network meta-analyses. It lies within haloperidol's existing psychiatric area, so it is better seen as an extension than as novel repurposing. It could proceed with guardrails: monitoring for extrapyramidal symptoms, QT prolongation and tardive dyskinesia, and managing the high interaction burden.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.